Cannabis in Asia: its center of origin and early cultivation, based on a synthesis of subfossil pollen and archaeobotanical studies

Biogeographers assign the center of origin of Cannabis to Central Asia, mostly based on wildtype plant distribution data. We sought greater precision by adding new data: 155 fossil pollen studies (FPSs) in Asia. Many FPSs assign pollen of Cannabis or Humulus (C-H) to collective names (e.g., Cannabis/Humulus or Cannabaceae). To dissect these aggregate data, we used ecological proxies. C-H pollen in a steppe assemblage (with Poaceae, Artemisia, Chenopodiaceae) was identified as wild-type Cannabis. C-H pollen in a forest assemblage (Alnus, Salix, Quercus, Betula, Robinia, Juglans) was identified as Humulus. C-H pollen curves that upsurged alongside crop pollen were identified as cultivated hemp. Subfossil seeds (achenes) at archaeological sites also served as evidence of cultivation. FPSs and archaeological sites were mapped using geographic information system (GIS) software. The oldest C-H pollen consistent with C. sativa dated to 19.6 million years ago (mya), in northwestern China. However, Cannabis and Humulus diverged 27.8 mya, based on molecular clock analysis. We bridged the temporal gap between the divergence date and the oldest pollen by mapping the earliest appearance of Artemisia. These data converge on the northeastern Tibetan Plateau, which we deduce as the C. sativa center of origin. This co-localizes with the first steppe community that evolved in Asia. From there, Cannabis first dispersed west (Europe by 6 mya) then east (eastern China by 1.2 mya). Cannabis pollen in South Asia appeared by 32.6 kya. The earliest Cannabis seeds were found in Japan, 10,000 BCE, followed by China

COSMOS2020: Identification of High-z Protocluster Candidates in COSMOS

We conduct a systematic search for protocluster candidates at $z \geq 6$ in the COSMOS field using the recently released COSMOS2020 source catalog. We select galaxies using a number of selection criteria to obtain a sample of galaxies that have a high probability of being inside a given redshift bin. We then apply overdensity analysis to the bins using two density estimators, a Weighted Adaptive Kernel Estimator and a Weighted Voronoi Tessellation Estimator. We have found 15 significant ($>4\sigma$) candidate galaxy overdensities across the redshift range $6\le z\le7.7$. The majority of the galaxies appear to be on the galaxy main sequence at their respective epochs. We use multiple stellar-mass-to-halo-mass conversion methods to obtain a range of dark matter halo mass estimates for the overdensities in the range of $\sim10^{11-13}\,M_{\rm \odot}$, at the respective redshifts of the overdensities. The number and the masses of the halos associated with our protocluster candidates are consistent with what is expected from the area of a COSMOS-like survey in a standard $\Lambda$CDM cosmology. Through comparison with simulation, we expect that all the overdensities at $z\simeq6$ will evolve into a Virgo-/Coma-like clusters at present (i.e., with masses $\sim 10^{14}-10^{15}\,M_{\rm \odot}$). Compared to other overdensities identified at $z \geq 6$ via narrow-band selection techniques, the overdensities presented appear to have $\sim10\times$ higher stellar masses and star-formation rates. We compare the evolution in the total star-formation rate and stellar mass content of the protocluster candidates across the redshift range $6\le z\le7.7$ and find agreement with the total average star-formation rate from simulations.Comment: 52 pages, 32 figues, 18 tables, main text is 30 pages, appendix is 22 pages, to be published in Ap

Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship

Previous research has shown that academic physicians conflicted by funding from the pharmaceutical industry have corrupted evidence based medicine and helped enlarge the market for drugs. Physicians made pharmaceutical-friendly statements, engaged in disease mongering, and signed biased review articles ghost-authored by corporate employees. This paper tested the hypothesis that bias affects review articles regarding rimonabant, an anti-obesity drug that blocks the central cannabinoid receptor.A MEDLINE search was performed for rimonabant review articles, limited to articles authored by USA physicians who served as consultants for the company that manufactures rimonabant. Extracted articles were examined for industry-friendly bias, identified by three methods: analysis with a validated instrument for monitoring bias in continuing medical education (CME); analysis for bias defined as statements that ran contrary to external evidence; and a tally of misrepresentations about the endocannabinoid system. Eight review articles were identified, but only three disclosed authors' financial conflicts of interest, despite easily accessible information to the contrary. The Takhar CME bias instrument demonstrated statistically significant bias in all the review articles. Biased statements that were nearly identical reappeared in the articles, including disease mongering, exaggerating rimonabant's efficacy and safety, lack of criticisms regarding rimonabant clinical trials, and speculations about surrogate markers stated as facts. Distinctive and identical misrepresentations regarding the endocannabinoid system also reappeared in articles by different authors.The findings are characteristic of bias that arises from financial conflicts of interest, and suggestive of ghostwriting by a common author. Resolutions for this scenario are proposed

Size - Stellar Mass Relation and Morphology of Quiescent Galaxies at z≥3z\geq3 in Public JWSTJWST Fields

We present the results of a systematic study of the rest-frame optical morphology of quiescent galaxies at $z \geq 3$ using the Near-Infrared Camera (NIRCam) onboard $JWST$. Based on a sample selected by $UVJ$ color or $NUVUVJ$ color, we focus on 26 quiescent galaxies with $9.8<\log{(M_\star/M_\odot)}<11.4$ at $2.8<z_{\rm phot}<4.6$ with publicly available $JWST$ data. Their sizes are constrained by fitting the S\'ersic profile to all available NIRCam images. We see a negative correlation between the observed wavelength and the size in our sample and derive their size at the rest-frame $0.5\, {\rm \mu m}$ taking into account this trend. Our quiescent galaxies show a significant correlation between the rest-frame $0.5\, {\rm \mu m}$ size and the stellar mass at $z\geq3$. The analytical fit for them at $\log{(M_\star/M_\odot)}>10.3$ implies that our size - stellar mass relations are below those at lower redshifts, with the amplitude of $\sim0.6\, {\rm kpc}$ at $M_\star = 5\times 10^{10}\, M_\odot$. This value agrees with the extrapolation from the size evolution of quiescent galaxies at $z<3$ in the literature, implying that the size of quiescent galaxies increases monotonically from $z\sim3-5$. Our sample is mainly composed of galaxies with bulge-like structures according to their median S\'ersic index and axis ratio of $n\sim3-4$ and $q\sim0.6-0.8$, respectively. On the other hand, there is a trend of increasing fraction of galaxies with low S\'ersic index, suggesting $3<z<5$ might be the epoch of onset of morphological transformation with a fraction of very notable disky quenched galaxies.Comment: 23 pages, 16 figures, 2 tables; submitted to Ap

TRY plant trait database – enhanced coverage and open access

Plant traits - the morphological, anatomical, physiological, biochemical and phenological characteristics of plants - determine how plants respond to environmental factors, affect other trophic levels, and influence ecosystem properties and their benefits and detriments to people. Plant trait data thus represent the basis for a vast area of research spanning from evolutionary biology, community and functional ecology, to biodiversity conservation, ecosystem and landscape management, restoration, biogeography and earth system modelling. Since its foundation in 2007, the TRY database of plant traits has grown continuously. It now provides unprecedented data coverage under an open access data policy and is the main plant trait database used by the research community worldwide. Increasingly, the TRY database also supports new frontiers of trait‐based plant research, including the identification of data gaps and the subsequent mobilization or measurement of new data. To support this development, in this article we evaluate the extent of the trait data compiled in TRY and analyse emerging patterns of data coverage and representativeness. Best species coverage is achieved for categorical traits - almost complete coverage for ‘plant growth form’. However, most traits relevant for ecology and vegetation modelling are characterized by continuous intraspecific variation and trait–environmental relationships. These traits have to be measured on individual plants in their respective environment. Despite unprecedented data coverage, we observe a humbling lack of completeness and representativeness of these continuous traits in many aspects. We, therefore, conclude that reducing data gaps and biases in the TRY database remains a key challenge and requires a coordinated approach to data mobilization and trait measurements. This can only be achieved in collaboration with other initiatives

A.T. Still Quote Collection

A page of quotations collected by Dr. McPartland from Doctor A.T. Still in the Living: His Concepts and Principles of Health and Disease by R.E. Truhlar and Dr. A.T. Still.https://dune.une.edu/mcpartlandcollection/1000/thumbnail.jp